Revolutionizing Single-Cell Research with Automation
BD (Becton, Dickinson and Company) (NYSE: BDX), a prominent player in the medical technology sector, has announced an exciting advancement in laboratory automation technology. This new initiative focuses on high-throughput, robotics-compatible reagent kits designed to automate and standardize single-cell discovery studies, significantly improving efficiency and consistency in genomic sequencing.
The Significance of Automation in Genomic Landscape
Modern scientific inquiry is increasingly reliant on rapid and accurate results. Historically, the preparation of genetic material, essential for DNA libraries in single-cell studies, has been a time-consuming endeavor filled with manual processes that often compromise data quality. This innovation marks a pivotal shift, enabling researchers to streamline these steps through automation, thereby reducing variability and ensuring consistent outcomes.
BD and Hamilton Collaboration
This remarkable automation solution is a product of the collaboration between BD and Hamilton, leveraging Hamilton's Microlab NGS STAR liquid handling platform. The synergy between these two companies exemplifies dedication to enhancing scientific research capabilities. These newly launched BD OMICS-One XT WTA Assay reagent kits are specifically designed to operate seamlessly with Hamilton's systems, making it easier for laboratories worldwide to implement this cutting-edge technology.
Enhancing Consistency and Efficiency
As researchers focus on scaling their work, the importance of consistent results becomes paramount. Steve Conly, the worldwide president of BD Biosciences, emphasizes that automating the library preparation process not only scales sample throughput but also mitigates the impact of human error, enriching the scientific community's capacity for innovation in areas such as oncology and immunology.
Expanding Access to Groundbreaking Solutions
The BD OMICS-One XT Library Preparation Reagent Kits are now commercially available, allowing for easy access to state-of-the-art laboratory solutions. Researchers can purchase the Hamilton Microlab NGS STAR platform and BD's reagent kits through various channels, including BD representatives and e-commerce portals in selected regions. This availability signifies BD's commitment to support researchers across various genomic applications.
About BD: Pioneering Health Innovations
BD stands as one of the largest global medical technology companies, tirelessly working to improve health through innovative solutions. With over 70,000 dedicated employees, BD focuses on enhancing medical discovery and diagnostics while ensuring the safety and efficacy of care delivery. The organization's commitment to addressing critical global health challenges is reflected in its collaborative efforts with healthcare providers and researchers worldwide. For further information about BD and its initiatives, please visit bd.com or connect on major social media platforms.
Frequently Asked Questions
What is the main purpose of BD's new robotics solution?
BD's new robotics solution aims to automate and standardize single-cell discovery studies, enhancing efficiency and consistency in genomic sequencing.
How does the BD OMICS-One XT WTA Assay improve research?
The BD OMICS-One XT WTA Assay improves research by streamlining the often labor-intensive library preparation process, allowing for increased throughput and better data quality.
What role does Hamilton play in this new automation?
Hamilton provides the Microlab NGS STAR liquid handling platform that integrates with BD's reagent kits for seamless laboratory workflows.
In which research areas can this technology be particularly beneficial?
This technology is beneficial in critical areas such as oncology and immunology, where precise genomic analysis is essential.
Where can researchers purchase these new BD products?
Researchers can purchase the BD OMICS-One XT Reagent Kits and Hamilton Microlab NGS STAR platform through BD representatives or selected e-commerce portals.
